Molecular prognostic markers in breast cancer

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 185-200

  Dahiya, Rajvir ^a,b   Deng, Guoren ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA 1 and BRCA 2; Chromosomal aberrations; erbB oncogenes; LOH; Microsatellite instability; Multidrug resistance (MDR) gene; p53; TGF

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MARKER; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA;

BREAST CANCER; CHROMOSOME ABERRATION; FEMALE; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; MULTIDRUG RESISTANCE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0032445261     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006101729631     Document Type: Review

References (87)

1. Brenner AJ, Aldaz CM: The genetics of sporadic breast cancer. Prog Clin Biol Res 396:63-82, 1997
2. Dhingra K, Hittelman WN, Hortobagyi GN: Genetic changes in breast cancer - consequences for therapy? Gene 159:59-63, 1995
3. Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 4th ed. J.B. Lippincott, Philadelphia, 1993, pp 1264-1332
4. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1. Science 266:66-71, 1994
5. Volgelstein B, Kinzler KW: Has the breast cancer gene been found? Cell 79:1-3, 1994
6. Hall JM, Lee MK, Newman B: Linkage of early onset familial breast cancer and ovarian cancer to chromosome 17q21. Science 250:1684-1689, 1990
7. Futreal PA, Liu Q, Shattuck-Eidens D: BRCA-1 mutations in primary breast and ovarian carcinomas. Science 266:120-22, 1994
8. Fitzgerald MG, Macdonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA: Germ-line BRCA-1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334:143-149, 1996
9. Eisenger F, Lyonnet DS, Longy M, Kerangueven F, Noguchi T, Bailly C, Salmon AV, Jacquemier J, Birnbaum D, Sobol H: Germ-line mutation at BRCA-1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56:471-474, 1996
10. Stratton RM: Recent advances in understanding of genetic susceptibility to breast cancer. Human Mol Genet 5:1515-1519, 1996
11. Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ogmundsdottir HM, Eyfjord JE: Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 105:121-130, 1997
12. Moll UM, Ostermeyer AG, Ahomadegbe JC, Mathieu MC, Riou G: p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Human Pathol 26:1293-1301, 1995
13. Eyfjord JE, Thorlacius S, Valgardsdottir R, Gretarsdottir S, Steinarsdottir M, Anamthawat-Jonsson K: TP53 abnormalities and genetic instability in breast cancer. Acta Oncologica 34:663-667, 1995
14. Jardines L, Weiss M, Fowble B, Greene M: Neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61:268-282, 1993
15. Ushiro H, Cohen S: Identification of phosphorylation as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem 255:8363-8365, 1980
16. Schlessinger J: Regulation of cell growth by the EGF receptor. In: Kahn P, Graf T (eds) Oncogenes and Growth Control. Springer, Heidelberg, 1986, pp 77-84
17. Yamamoto T, Shuntaro I, Akiyama T, Semba K, Nomura N, Miyajima N, Saeto T, Toyoshima K: Similarity of protein encoded by the human c-erbB gene to the epidermal growth factor receptor. Nature 319:230-234, 1986
18. Yarden Y, Schlessinger J: Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26:1443-1451, 1987
19. Delarue J, Friedman S, Mouriesse H, May-Levin F, Sancho-Garnier H, Contesso G: Epidermal growth factor receptor in human breast cancers. Correlation with estrogen and progesterone receptors. Breast Cancer Res Treat 11:173-178, 1988
20. Macias A, Perez R, Hagestrom T, Skoog L: Identification of transforming growth factor alpha in human primary breast carcinoma. Anticancer Res 7:1271-1276, 1987
21. Sainsbury J, Farndon J, Sherbet G, Harris A: Epidermal growth factor receptors and estrogen receptors in human breast cancer. Lancet i:364-366,1985
22. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i:1398-1402,1987
23. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB-2 and the EGF receptor genes in inflammatory breast cancer and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 43:201-208, 1989
24. Battaglia F, Scambia G, Rossi S, Panici PB, Bellantone R, Polizzi G, Overzoli P, Negrini R, Iacobelli S, Crucitti F, Mancuso S: Epidermal growth factor receptor in human breast cancer: Correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol 24:1685-1690, 1988
25. Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, Testotin A, La Malfa G, Pozza F: Human breast cancer: Prognostic significance of the expression of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686-695, 1992
26. Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CHW: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
27. Tripathy D, Benz CC: Growth factors and their receptors. In: Shapiro CL, Henderson IC (eds) New Directions in Breast Cancer Research and Therapeutics. Hematology/Oncology Clinics of North America 8:29-50, 1994
28. Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657, 1986
29. Coussens L, Yang-Feng T, Liao Y: Tyrosine kinase receptor with extensive homology to the EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1134, 1985
30. Akiyama T, Sudo C, Ogawara U, Toyoshima T, Yamamoto T: The product of the human c-erbB-2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
31. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: The neu oncogene: An erb-B related gene coding a 185,000-Mr tumor antigen. Nature 312:513-516, 1984
32. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
33. Ro J, El-Naggar A, Ro JY, Blich M, Frye D, Fraschine G, Fritsche H, Hortobagyi G: c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49:6941-6944, 1989
34. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related protooncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 63:605-610, 1987
35. Nagai MA, Marques LA, Torloni H, Brenti MM: Genetic alterations in c-erbB-2 proto-oncogene as a prognostic marker in human primary breast tumors. Oncology 50:412-417, 1993
36. Eissa S, Amina El-Ghaich K, Salah N, Mohammed MK: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res 17:1417-1424, 1997
37. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J Cairns J, Harris AL, Horne CHW: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
38. De Potter CR, Schelflhout AM: The neu protein and breast cancer. Virchows Arch 426:107-115, 1995
39. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD, Page DL: Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 150:1925-1932, 1997
40. Sourvinos G, Kiaris H, Tsikkinis A, Vassilaros S, Spandidos DA: Microsatellite instability and loss of heterozygosity in primary breast tumours. Tumour Biol 18:157-166, 1997
41. Bergthorsson JT, Eiriksdottir G, Barkardottir RB, Egilsson V, Arason A, Ingvarsson S: Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3. Human Genetics 96:437-443, 1995
42. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS: Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057-2059, 1996
43. Widschwendter M, Berger J, Daxenbichler G, Muller-Holzner E, Widschwendter A, Mayr A, Marth C, Zeimet AG: Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 57:4158-4161, 1997
44. Yaremko ML, Recant WM, Westbrook CA: Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chrom Cancer 13:186-191, 1995
45. Dahiya R, Perinchery G, Deng G, Lee C: Multiple sites of loss of heterozygosity on chromosome 8 in human breast cancer has differential correlation with clinical parameters. Int J Oncol 12:811-816, 1998
46. Huang TH, Yeh PL, Martin MB, Straub RE, Gilliam TC, Caldwell CW, Skibba JL: Genetic alterations of microsatellites on chromosome 18 in human breast carcinoma. Diag Mol Pathol 4:66-72, 1995
47. Eiriksdottir G, Sigurdsson A, Jonasson JG, Agnarsson BA, Sigurdsson H, Gudmundsson J, Bergthorsson JT, Barkardottir RB, Egilsson V, Ingvarsson S: Loss of heterozygosity on chromosome 9 in human breast cancer: Association with clinical variables and genetic changes at other chromosome regions. Int J Cancer 64:378-382, 1995
48. Deng G, Chen L-C, Schott DR, Thor A, Bhargava V, Ljung B-M, Chew K, Smith HS: Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54:499-505, 1994
49. Hittelman WN, Kim HJ, Lee JS, Shin DM, Lippman SM, Kim J, Ro JY, Hong WK: Detection of chromosome instability of tissue fields at risk: in situ hybridization. J Cell Biochem 25:57-62, 1996
50. Fiegl M, Tueni C, Schenk T, Jakesz R, Gnant M, Reiner A, Rudas M, Pirc-Danoewinata H, Marosi C, Huber H, et al: Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancer. Br J Cancer 72:51-55, 1995
51. Devilee P, Van de Vijver M, Schurring E, Cornelisse C: Recent development in the molecular genetics of human primary breast cancer. Crit Rev Oncogene 6:1705-1711, 1994
52. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91:9871-9875, 1994
53. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator-gene homolog MSH2 and its association with hereditary non-polyposis colorectal cancer. Cell 75:1027-1038, 1993
54. Modrich P: Mechanisms and biological effects of mismatch repair. Ann Rev Genet 25:229-253 1991
55. Dahiya R: DNA repair genes in human fetal and adult prostatic tissues and cancer cell lines using differential RT-PCR. Urol Oncol 2:52-56, 1996
56. Shaw JA, Walsh T, Chappell SA, Carey N, Johnson K, Walker RA: Microsatellite instability in early sporadic breast cancer. Br J Cancer 73:1393-1397, 1996
57. Karnik P, Plummer S, Casey G, Myles J, Tubbs R, Crowe J, Williams BR: Microsatellite instability at a single locus (D11S988) on chromosome 11p15.5 as a late event in mammary tumorigenesis. Human Mol Genetics 4:1889-1894, 1995
58. Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J: Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 77:1836-1843, 1996
59. Toyama T, Iwase H, Yamashita H, Iwata H, Yamashita T, Ito K, Yasuo H, Suchi M, Kato T, Nakamura T, Kobayashi S: Microsatellite instability in sporadic human breast cancers. Int J Cancer 68:447-451, 1996
60. Contegiacomo A, Palmirotto R, DeMarchis L, Pizzi C, Mastranzo P, Delrio P, Petrella G, Figliolini M, Bianco AR, Frati L, Cama A, Costantini RM: Microsatellite instability and pathological aspects of breast cancer. Int J Cancer 64:264-268, 1995
61. Marx J: DNA repair comes into its own. Science 266:728-730, 1994
62. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopolous P, Peltomaki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B: Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Gen 9:48-55, 1995
63. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin, JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Peterson GM, Kinzler KW, Vogelstein B, de la Chapelle A: Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816, 1993
64. Jonsson M, Johannsson O, Borg A: Infrequent occurrence of microsatellite instability in sporadic and familial breast cancer. Eur J Cancer 31A:2330-2334, 1995
65. Loeb LA: Microsatellite instability: Marker of a mutator phenotype in cancer. Cancer Res 54:5059-5063, 1994
66. Glebov OK, McKenzie KE, White CA, Sukumar S: Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 54:3703-3709, 1994
67. Dahiya R, Lee C, Deng G, Thompson H: Microsatellite instability in an animal model of mammary carcinogenesis. Int J Oncol 13:23-28, 1998
68. Weber JL: Informativeness of human (dC-dA)n (dG-dT)n polymorphisms. Genomics 7:524-530, 1990
69. Weber J, Wong C: Mutation of human short tandem repeats. Human Mol Genet 2:1123-1128, 1993
70. Lindstedt BA, Ryberg D, Haugen A: Rare alleles at different VNTR loci among lung cancer patients with microsatellite instability in tumors. Int J Cancer 70:412-415, 1997
71. Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Lahti MN, Seruca R, David L, Holm R, Ryberg D, Haugen A, Brogger A, Borressen AL, de la Chapelle A: Microsatellite instability is associated with tumors that characterise the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53:5853-5855, 1993
72. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146-151, 1985
73. London SJ, Connolly JL, Schnitt SI, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. J Am Med Assoc 267:941-944, 1992
74. Rosenberg CL, de las Morenas A, Huang K, Cupples LA, Faller DV, Larson PS: Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J Clin Invest 98:1095-1100, 1996
75. Fialkow PJ: Clonal origin of human tumors. Biochem Biophys Acta 458:283-321, 1976
76. Nowell PC: The clonal evolution of tumor cell populations. Science 94:23-28, 1976
77. Kunkel TA: Nucleotide repeats: slippery DNA and diseases. Nature 365:207-208, 1993
78. Rosenberg CL, Larson PS, Romo JD, De Las Morenas A, Faller DV: Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Human Pathol 28:214-219, 1997
79. Derynck R: Transforming growth factor α. In: Kahn P, Graft T (eds) Oncogene and Growth Control. Springer, Heidelberg, 1986, pp 58-64
80. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS: Expression of transforming growth factor alpha (and its messenger ribonucleic acid) in human breast cancer: Its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543-555,1988
81. Marquardt H, Hunkapiller MW, Hood LE, Todaro GJ: Rat transforming growth factor type I: structure and relation to epidermal growth factor. Science 223:1079-1082, 1984
82. Brachman R, Lindquist PB, Nagashima M, Kohr W, Lipari T, Napier M, Derynck R: Transmembrane TGFα precursors activate EGF/TGFα receptors. Cell 56:691-700, 1989
83. Perroteau I, Salomon D, DeBortoli M, Kidwell W, Hazarika P, Pardue R, Dedman J, Tam J: Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cells. Breast Cancer Res Treat 7:201-210, 1986
84. Salomon DS, Kidwell WR, Liu S, Kim N, Callahan R, Theillet C, Lidereau R, Derynck R: Presence of alpha TGF mRNA in human breast cancer cell lines and in human breast carcinomas [abstract]. Breast Cancer Res Treat 8:106, 1986
85. Rosenthal A, Lindquist PB, Bringman TS, Goeddel DV, Derynck R: Expression in rat fibroblast of a human transforming factor cDNA results in transformation. Cell 46:301-309, 1986
86. Matsui Y, Halter H, Holt JT, Hogen BLM, Coffey RJ: Development of mammary hyperplasia and neoplasia in MMTV-TGFβ transgenic mice. Cell 61:1147-1155, 1990
87. Bodey B, Bodey B Jr, Groger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance. Anticancer Res 17:1311-1318, 1997